These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 14664197)

  • 21. Recombinant human erythropoietin treatment for chemotherapy-related anemia in children.
    Varan A; Büyükpamukçu M; Kutluk T; Akyüz C
    Pediatrics; 1999 Feb; 103(2):E16. PubMed ID: 9925862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative studies of erythropoiesis in the clinically normal, phlebotomized, and feline leukemia virus-infected cat.
    Wardrop KJ; Kramer JW; Abkowitz JL; Clemons G; Adamson JW
    Am J Vet Res; 1986 Oct; 47(10):2274-7. PubMed ID: 3022625
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treating anemia associated with chronic renal failure with erythropoiesis stimulators: recombinant human erythropoietin might be the best among the available choices.
    Trkulja V
    Med Hypotheses; 2012 Jan; 78(1):157-61. PubMed ID: 22078846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients.
    Jungers P; Choukroun G; Oualim Z; Robino C; Nguyen AT; Man NK
    Nephrol Dial Transplant; 2001 Feb; 16(2):307-12. PubMed ID: 11158405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia.
    Mittelman M; Zeidman A; Fradin Z; Magazanik A; Lewinski UH; Cohen A
    Acta Haematol; 1997; 98(4):204-10. PubMed ID: 9401498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Borrelia persica infection in dogs and cats: clinical manifestations, clinicopathological findings and genetic characterization.
    Baneth G; Nachum-Biala Y; Halperin T; Hershko Y; Kleinerman G; Anug Y; Abdeen Z; Lavy E; Aroch I; Straubinger RK
    Parasit Vectors; 2016 May; 9(1):244. PubMed ID: 27160515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Follow-up of very low birth weight infants after erythropoietin treatment to prevent anemia of prematurity.
    Soubasi V; Kremenopoulos G; Diamanti E; Tsantali C; Sarafidis K; Tsakiris D
    J Pediatr; 1995 Aug; 127(2):291-7. PubMed ID: 7636658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure.
    Ahluwalia N; Skikne BS; Savin V; Chonko A
    Am J Kidney Dis; 1997 Oct; 30(4):532-41. PubMed ID: 9328369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential uses of recombinant human factor VIIa in veterinary medicine.
    Kristensen AT; Edwards ML; Devey J
    Vet Clin North Am Small Anim Pract; 2003 Nov; 33(6):1437-51. PubMed ID: 14664207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EPO: renoprotection beyond anemia correction.
    Fliser D; Bahlmann FH; Haller H
    Pediatr Nephrol; 2006 Dec; 21(12):1785-9. PubMed ID: 16957890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
    Dimković N
    Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant human erythropoietin in cancer-related anemia. Review of clinical evidence.
    Crawford J
    Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):41-53. PubMed ID: 12380954
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.
    Rainville N; Jachimowicz E; Wojchowski DM
    Expert Opin Ther Targets; 2016; 20(3):287-301. PubMed ID: 26419263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hematopoietic growth factors: frontiers for cure.
    Ogilvie GK
    Vet Clin North Am Small Anim Pract; 1995 Nov; 25(6):1441-56. PubMed ID: 8619275
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model.
    Woodburn KW; Fan Q; Winslow S; Chen MJ; Mortensen RB; Casadevall N; Stead RB; Schatz PJ
    Exp Hematol; 2007 Aug; 35(8):1201-8. PubMed ID: 17662888
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Erythropoietin and the anemia of chronic diseases.
    De Marchi S; Pirisi M; Ferraccioli GF
    Clin Exp Rheumatol; 1993; 11(4):429-44. PubMed ID: 8403591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents.
    Tanaka T; Nangaku M
    Exp Cell Res; 2012 May; 318(9):1068-73. PubMed ID: 22414872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erythropoietin and chronic lymphocytic leukemia.
    Mauro FR; Gentile M; Foa R
    Rev Clin Exp Hematol; 2002; Suppl 1():21-31. PubMed ID: 12735212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel aspects of erythropoietin response in renal failure patients.
    Sunder-Plassmann G; Hörl WH
    Nephrol Dial Transplant; 2001; 16 Suppl 5():40-4. PubMed ID: 11509683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Erythropoietin--physiology and therapeutic potentialities].
    Möllmann M
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1992 Dec; 27(8):461-8. PubMed ID: 1489869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.